UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months. However, resistance often occurs, largely limits its efficacy. Sorafenib was found to target the elect...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Signal Transduct Target Ther
Main Authors: Xu, Junjie, Ji, Lin, Ruan, Yeling, Wan, Zhe, Lin, Zhongjie, Xia, Shunjie, Tao, Liye, Zheng, Junhao, Cai, Liuxin, Wang, Yifan, Liang, Xiao, Cai, Xiujun
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group UK 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129126/
https://ncbi.nlm.nih.gov/pubmed/34001851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00594-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים